|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC25A16 |
Gene summary for SLC25A16 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC25A16 | Gene ID | 8034 |
| Gene name | solute carrier family 25 member 16 | |
| Gene Alias | D10S105E | |
| Cytomap | 10q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B4DHV9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8034 | SLC25A16 | LZE4T | Human | Esophagus | ESCC | 6.18e-04 | 1.57e-01 | 0.0811 |
| 8034 | SLC25A16 | LZE7T | Human | Esophagus | ESCC | 5.27e-06 | 2.30e-01 | 0.0667 |
| 8034 | SLC25A16 | LZE22T | Human | Esophagus | ESCC | 9.43e-04 | 2.16e-01 | 0.068 |
| 8034 | SLC25A16 | LZE24T | Human | Esophagus | ESCC | 1.59e-16 | 4.08e-01 | 0.0596 |
| 8034 | SLC25A16 | LZE21T | Human | Esophagus | ESCC | 4.66e-03 | 2.64e-01 | 0.0655 |
| 8034 | SLC25A16 | P1T-E | Human | Esophagus | ESCC | 3.25e-13 | 3.95e-01 | 0.0875 |
| 8034 | SLC25A16 | P2T-E | Human | Esophagus | ESCC | 1.53e-19 | 2.51e-01 | 0.1177 |
| 8034 | SLC25A16 | P4T-E | Human | Esophagus | ESCC | 2.78e-14 | 2.68e-01 | 0.1323 |
| 8034 | SLC25A16 | P5T-E | Human | Esophagus | ESCC | 3.60e-13 | 2.40e-01 | 0.1327 |
| 8034 | SLC25A16 | P8T-E | Human | Esophagus | ESCC | 9.53e-09 | 1.24e-01 | 0.0889 |
| 8034 | SLC25A16 | P9T-E | Human | Esophagus | ESCC | 1.08e-03 | 8.58e-02 | 0.1131 |
| 8034 | SLC25A16 | P10T-E | Human | Esophagus | ESCC | 4.31e-06 | 1.18e-01 | 0.116 |
| 8034 | SLC25A16 | P11T-E | Human | Esophagus | ESCC | 1.29e-05 | 2.72e-01 | 0.1426 |
| 8034 | SLC25A16 | P12T-E | Human | Esophagus | ESCC | 5.79e-16 | 2.13e-01 | 0.1122 |
| 8034 | SLC25A16 | P15T-E | Human | Esophagus | ESCC | 8.22e-10 | 1.89e-01 | 0.1149 |
| 8034 | SLC25A16 | P16T-E | Human | Esophagus | ESCC | 1.76e-12 | 1.49e-01 | 0.1153 |
| 8034 | SLC25A16 | P20T-E | Human | Esophagus | ESCC | 1.43e-11 | 2.94e-01 | 0.1124 |
| 8034 | SLC25A16 | P21T-E | Human | Esophagus | ESCC | 3.28e-14 | 2.68e-01 | 0.1617 |
| 8034 | SLC25A16 | P22T-E | Human | Esophagus | ESCC | 9.02e-11 | 1.70e-01 | 0.1236 |
| 8034 | SLC25A16 | P23T-E | Human | Esophagus | ESCC | 2.50e-12 | 2.34e-01 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006839110 | Esophagus | ESCC | mitochondrial transport | 187/8552 | 254/18723 | 8.35e-20 | 9.81e-18 | 187 |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
| GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
| GO:0009150111 | Esophagus | ESCC | purine ribonucleotide metabolic process | 213/8552 | 368/18723 | 1.40e-06 | 1.69e-05 | 213 |
| GO:0046390110 | Esophagus | ESCC | ribose phosphate biosynthetic process | 119/8552 | 190/18723 | 1.73e-06 | 2.06e-05 | 119 |
| GO:0006163111 | Esophagus | ESCC | purine nucleotide metabolic process | 226/8552 | 396/18723 | 2.81e-06 | 3.21e-05 | 226 |
| GO:000916516 | Esophagus | ESCC | nucleotide biosynthetic process | 150/8552 | 254/18723 | 1.12e-05 | 1.06e-04 | 150 |
| GO:0009260110 | Esophagus | ESCC | ribonucleotide biosynthetic process | 112/8552 | 182/18723 | 1.12e-05 | 1.06e-04 | 112 |
| GO:190129316 | Esophagus | ESCC | nucleoside phosphate biosynthetic process | 151/8552 | 256/18723 | 1.15e-05 | 1.08e-04 | 151 |
| GO:00338664 | Esophagus | ESCC | nucleoside bisphosphate biosynthetic process | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:00340304 | Esophagus | ESCC | ribonucleoside bisphosphate biosynthetic process | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:00340334 | Esophagus | ESCC | purine nucleoside bisphosphate biosynthetic process | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:007252217 | Esophagus | ESCC | purine-containing compound biosynthetic process | 120/8552 | 200/18723 | 3.02e-05 | 2.51e-04 | 120 |
| GO:0009152110 | Esophagus | ESCC | purine ribonucleotide biosynthetic process | 103/8552 | 169/18723 | 4.40e-05 | 3.51e-04 | 103 |
| GO:000616417 | Esophagus | ESCC | purine nucleotide biosynthetic process | 113/8552 | 191/18723 | 1.16e-04 | 8.04e-04 | 113 |
| GO:00338655 | Esophagus | ESCC | nucleoside bisphosphate metabolic process | 77/8552 | 128/18723 | 6.71e-04 | 3.55e-03 | 77 |
| GO:00338755 | Esophagus | ESCC | ribonucleoside bisphosphate metabolic process | 77/8552 | 128/18723 | 6.71e-04 | 3.55e-03 | 77 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC25A16 | SNV | Missense_Mutation | c.983N>C | p.Phe328Ser | p.F328S | P16260 | protein_coding | tolerated(0.17) | benign(0.216) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC25A16 | SNV | Missense_Mutation | novel | c.119T>G | p.Phe40Cys | p.F40C | P16260 | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC25A16 | SNV | Missense_Mutation | c.890G>T | p.Arg297Leu | p.R297L | P16260 | protein_coding | tolerated(0.67) | benign(0.047) | TCGA-JW-A5VI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | topotecan | PD | |
| SLC25A16 | SNV | Missense_Mutation | novel | c.781T>A | p.Phe261Ile | p.F261I | P16260 | protein_coding | deleterious(0.02) | benign(0.1) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC25A16 | SNV | Missense_Mutation | c.656N>T | p.Ser219Phe | p.S219F | P16260 | protein_coding | tolerated(0.1) | possibly_damaging(0.482) | TCGA-AZ-4313-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC25A16 | SNV | Missense_Mutation | rs747313620 | c.967G>A | p.Glu323Lys | p.E323K | P16260 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SLC25A16 | SNV | Missense_Mutation | novel | c.191N>C | p.Leu64Ser | p.L64S | P16260 | protein_coding | deleterious(0) | benign(0.314) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SLC25A16 | SNV | Missense_Mutation | c.374N>C | p.Leu125Pro | p.L125P | P16260 | protein_coding | deleterious(0.02) | possibly_damaging(0.761) | TCGA-A5-A0GW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SLC25A16 | SNV | Missense_Mutation | rs139107749 | c.889N>G | p.Arg297Gly | p.R297G | P16260 | protein_coding | tolerated(0.33) | possibly_damaging(0.489) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLC25A16 | SNV | Missense_Mutation | novel | c.398N>A | p.Arg133Lys | p.R133K | P16260 | protein_coding | tolerated(1) | benign(0.145) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |